Abstract:Hypoxia-ischemia is the most common cause of neonatal encephalopathy (NE). In most cases, an intrapartum event is presumed to lead to perinatal hypoxia ischemia, but the exact pathogenesis, and therefore timing, are often not known. 1 In well-resourced settings, therapeutic hypothermia (TH) reduces death and major neurodevelopmental disability in infants with NE. 2 However, there is heterogeneity in outcomes, and major neurodevelopmental disability is still seen in about one third of survivors who are treated with therapeutic hypothermia. 3 The heterogeneity in response of NE to TH means alternative treatments are desperately sought. As such, many biomarkers have been studied as surrogate measures of long-term outcome, in order to expedite assessment of potential treatments. Moreover, an important goal is to personalize treatment for NE such that individuals who might benefit from a different approach to TH, might be detected early. It is also important to study biomarkers that can discriminate between which babies benefit from TH versus those who may be at higher risk of an adverse outcome. 4 In the study by O'Gorman Tuura et al., the authors have explored the link between perfusion and neurodevelopmental outcomes using arterial spine labeling (ASL) as a neuroimaging marker for outcome prediction. 5 ASL is a noninvasive magnetic resonance imaging (MRI) technique in which protons in blood and water are magnetically labeled and the signal generated by the endogenous labels are detected by subtracting MRI signals during alternating labeled and unlabeled acquisitions. The images demonstrate signal intensity proportional to the amount of perfusion in each voxel and a quantitative measurement of cerebral blood flow (CBF) can be calculated. 6 Previous authors have described patterns of CBF using ASL in NE. Wintermark et al. demonstrated initial hypoperfusion on day 1 followed by hyperperfusion at days 2–3. 7 A study by Tang et al. reported lower CBF values in neonates with NE at 0–24 h and 3–7 days with higher values in the 1–3 day-old group. 8 The mean age at MRI in O'Gorman Tuura's paper was 5 days (range 3–9 days), which means that any hyperperfusion identified may not represent the 'peak' perfusion phase, but rather the tail end of the more severe cases. The problem with that theory is that the cohort studied included infants with mild to moderate NE and the authors found a relationship between altered perfusion and outcome even in those children with mild to moderate impairment following NE.

Cerebral blood flow and serum neuron-specific enolase in early-onset neonatal sepsis

Utility of doppler ultrasound in early-onset neonatal sepsis: A case-control study

876 Neuron Specific Enolase and S-100 Protein in Sepsis Associated Encephalopathy (SAE)

Meta-analysis of evaluating neuron specific enolase as a serum biomarker for sepsis-associated encephalopathy

Cerebral Blood Flow Alterations in Sepsis-Associated Encephalopathy A Prospective Observational Study

The molecular basis of brain injury in preterm infants with sepsis - associated encephalopathy

Cerebral blood flow in neonatal encephalopathy: biomarker or potential target?

Cerebral Blood Flow Alterations in Sepsis‐Associated Encephalopathy

Clinical value of serum neuron-specific enolase in sepsis-associated encephalopathy: a systematic review and meta-analysis

Seizure Burden and Neurologic Outcomes After Neonatal Encephalopathy

Serum Neuron-Specific Enolase as a Biomarker of Neonatal Brain Injury-New Perspectives for the Identification of Preterm Neonates at High Risk for Severe Intraventricular Hemorrhage

Risk Factors for Sepsis-Associated Encephalopathy

Prognostic values of tumor necrosis factor-alpha, monocyte chemoattractant protein-1, and neuron-specific enolase in patients with sepsis-associated encephalopathy

Alterations in Regional Brain Microcirculation in Patients with Sepsis: A Prospective Study Using Contrast-Enhanced Brain Ultrasound

The Diagnostic Value of Neuron-Specific Enolase, Central Nervous System Specific Protein and Interleukin-6 in Sepsis-Associated Encephalopathy

Suspected or Proven Early-Onset Sepsis and NLR, PLR, and MPV Parameters in Neonates with Born through MSAF

Neonatal seizures during extra corporeal membrane oxygenation support

Changes of Serum Myelin Base Protein, Neuron Specific Enolase and Coronal-Ct Manifestions and Its Clinical Significance in Neonate Hypoxic Ischemic Encephalopathy

Elevated cerebral perfusion in neonatal encephalopathy is associated with neurodevelopmental impairments

Prognostic value of resistive index (measured in anterior cerebral artery) in term neonates with hypoxic ischemic encephalopathy

Using cerebral regional oxygen saturation and amplitude-integrated electroencephalography in neonates on extracorporeal membrane oxygenation: preliminary experience from a single center